var data={"title":"Follitropin alfa (recombinant human follicle stimulating hormone): Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Follitropin alfa (recombinant human follicle stimulating hormone): Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/7787?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=follitropin-alfa-recombinant-human-follicle-stimulating-hormone-patient-drug-information\" class=\"drug drug_patient\">see &quot;Follitropin alfa (recombinant human follicle stimulating hormone): Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3882602\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Gonal-f;</li>\n      <li>Gonal-f RFF;</li>\n      <li>Gonal-f RFF Pen [DSC];</li>\n      <li>Gonal-f RFF Rediject</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3888769\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Gonal-f;</li>\n      <li>Gonal-f  Pen</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3882605\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Gonadotropin;</li>\n      <li>\n        Ovulation Stimulator</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3882635\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Dose should be individualized. Use the lowest dose consistent with the expectation of good results. Over the course of treatment, doses may vary depending on individual patient response.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Ovulation induction:</b> Females: SubQ: Initial: 75 units daily; incremental dose adjustments of up to 37.5 units may be considered after 14 days; further dose increases of the same magnitude can be made, if necessary, every 7 days (maximum dose: 300 units daily). Treatment should be continued until follicular growth and/or serum estradiol levels indicate an adequate ovarian response. If response to follitropin is appropriate, hCG is given 1 day following the last dose to induce final oocyte maturation and ovulation. Withhold hCG if serum estradiol is &gt;2000 pg/mL; discontinue if the ovaries are abnormally enlarged, or if abdominal pain occurs. In general, therapy should not exceed 35 days.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Multifollicular development during ART:</b> Females: SubQ: Initiate therapy with follitropin alfa in the early follicular phase (cycle day 2 or day 3) at a dose of 150 units daily, until sufficient follicular development is attained. In most cases, therapy should not exceed 10 days. In patients &ge;35 years whose endogenous gonadotropin levels are suppressed, initiate follitropin alfa at a dose of 225 units daily. Continue treatment until adequate follicular development is indicated as determined by ultrasound in combination with measurement of serum estradiol levels. Consider adjustments to dose after 5 days based on the patient's response; adjust subsequent dosage every 3-5 days by &le;75-150 units additionally at each adjustment. Doses &gt;450 units daily are not recommended. Once adequate follicular development is evident, administer hCG to induce final follicular maturation in preparation for oocyte retrieval. Withhold hCG if the ovaries are abnormally enlarged.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Spermatogenesis induction:</b> Males: <i>Gonal-f:</i> SubQ: Therapy should begin with hCG pretreatment until serum testosterone is in normal range, then initiate Gonal-f at 150 units 3 times weekly with hCG 3 times weekly; continue with lowest dose needed to induce spermatogenesis (maximum dose: 300 units 3 times weekly); may be given for up to 18 months</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3882636\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing. Clinical studies did not include patients &gt;65 years. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13812856\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustment provided in the manufacturer's labeling (has not been studied).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13812857\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustment provided in the manufacturer's labeling (has not been studied).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F242582\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Subcutaneous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Gonal-f RFF Pen: 300 units/0.5 mL (0.5 mL [DSC]); 450 units/0.75 mL (0.75 mL [DSC]); 900 units/1.5 mL (1.5 mL [DSC]) [contains metacresol]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Gonal-f RFF Rediject: 300 units/0.5 mL (0.5 mL); 450 units/0.75 mL (0.75 mL); 900 units/1.5 mL (1.5 mL) [contains metacresol]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Injection: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Gonal-f: 450 units (1 ea); 1050 units (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Subcutaneous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Gonal-f RFF: 75 units (1 ea)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3882604\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3882637\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">SubQ: Administer SubQ. Contents of multidose vials (Gonal-f or Gonal-f RFF) should be administered using the calibrated syringes provided by the manufacturer. Do not shake solution; allow any bubbles to settle prior to administration. Allow Gonal-f RFF Rediject and Gonal-f RFF Pen to warm to room temperature for at least 30 minutes prior to administration to avoid discomfort from cold injection. Do not mix other medications inside of the Gonal-f RFF Rediject device.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F242583\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Multifollicular development during Assisted Reproductive Technology (ART):</b> To stimulate the development of multiple follicles with ART</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Ovulation induction:</b> Induction of ovulation and pregnancy in oligo-anovulatory infertile patients in whom the cause of infertility is functional and not caused by primary ovarian failure</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Spermatogenesis induction (Gonal-f only):</b> Induction of spermatogenesis in men with primary and secondary hypogonadotropic hypogonadism in whom the cause of infertility is not due to primary testicular failure</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3882614\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Percentage may vary by indication, product formulation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Varicocele (15%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Headache (13% to 27%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Acne vulgaris (males 59%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Ovarian cyst (4% to 15%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Abdominal pain (9% to 23%), nausea (4% to 14%), enlargement of abdomen (1% to 14%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Mastalgia (males 14%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Injection site reaction (males 15%; females 1% to 4%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Upper respiratory tract infection (4% to 12%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Chest pain (1% to 2%), hypotension (1% to 2%), palpitations (1% to 2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Fatigue (males 9%; females 1% to 2%), pain (2% to 6%), emotional lability (5%), migraine (1% to 4%), dizziness (1% to 3%), malaise (2%), anxiety (1% to 2%), drowsiness (1% to 2%), nervousness (1% to 2%), paresthesia (1% to 2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Acne vulgaris (females 4%), pruritus (1% to 2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Gynecomastia (9%), intermenstrual bleeding (4% to 9%), ovarian hyperstimulation syndrome (5% to 7%; severe: &lt;1%), weight gain (4%), menstrual disease (3%), hot flash (2%), ovarian disease (2%), increased thirst (1% to 2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Diarrhea (1% to 8%), flatulence (4% to 7%), toothache (1% to 4%), vomiting (1% to 3%), aphthous stomatitis (2%), constipation (2%), dyspepsia (2%), anorexia (1% to 2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Pelvic pain (7%), mastalgia (females 4% to 6%), vaginal hemorrhage (1% to 6%), cervical lesion (3%), genital candidiasis (3%), dysmenorrhea (1% to 3%), cystitis (2%), gynecological pain (2%), urinary frequency (2%), urinary tract infection (2%), uterine hemorrhage (2%), leukorrhea (1% to 2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Viral infection (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Bruising at injection site (10%), pain at injection site (3% to 9%), inflammation at injection site (1% to 4%), swelling at injection site (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Back pain (4% to 5%), myalgia (1% to 2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Rhinitis (&le;7%), pharyngitis (3% to 7%), sinusitis (5% to 6%), flu-like symptoms (4%), cough (2% to 3%), asthma (1% to 2%), dyspnea (1% to 2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Fever (2% to 4%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Postmarketing and/or case reports: Anaphylactoid reaction, anaphylaxis, depression, Epstein-Barr infection, hemoperitoneum, hemoptysis, hypersensitivity reaction, ovarian torsion, ovarian neoplasm, ovary enlargement, pulmonary complications (including atelectasis, acute respiratory distress syndrome, exacerbation of asthma), thromboembolism, vascular disease</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3882610\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to follitropins or any component of the formulation; high levels of FSH indicating primary gonadal failure (ovarian or testicular); sex hormone dependent tumors of the reproductive tract and accessory organs; intracranial lesions (eg, pituitary or hypothalamus tumor); uncontrolled thyroid, pituitary or adrenal dysfunction; abnormal uterine bleeding of undetermined origin; ovarian cysts or enlargement of undetermined origin not due to polycystic ovary syndrome; pregnancy </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3882611\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Abortion: Risk of spontaneous abortion is increased with the use of gonadotropins; causal effect has not been established.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Ectopic pregnancy: Risk for ectopic pregnancy may be increased in women with tubal abnormalities; intrauterine pregnancy should be confirmed early with hCG testing and transvaginal ultrasound.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity: Serious hypersensitivity reactions including anaphylaxis have been reported; discontinue use for serious reactions and treat appropriately.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Ovarian enlargement: May be accompanied by abdominal distention or abdominal pain, occurs in ~20% of those treated with urofollitropin and hCG, and generally regresses without treatment within 2 to 3 weeks. If ovaries are abnormally enlarged on the last day of treatment, withhold hCG to reduce the risk of ovarian hyperstimulation syndrome (OHSS).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Ovarian hyperstimulation syndrome (OHSS): OHSS is a rare exaggerated response to ovulation induction therapy (Corbett 2014; Fiedler 2012). This syndrome may begin within 24 hours of treatment but may become most severe 7 to 10 days after therapy (Corbett 2014). Symptoms of mild/moderate OHSS may include abdominal distention/discomfort, diarrhea, nausea, and/or vomiting. Severe OHSS symptoms may include severe abdominal pain, anuria/oliguria, ascites, severe dyspnea, hypotension, or nausea/vomiting (intractable). Decreased creatinine clearance, hemoconcentration, hypoproteinemia, elevated liver enzymes, elevated WBC, and electrolyte imbalances may also be present (ASRM 2016; Corbett 2014; Fiedler 2012). Treatment is primarily symptomatic and includes fluid and electrolyte management, analgesics, and prevention of thromboembolic complications (ASRM 2016; SOGC-CFAS 2011). Therapy with gonadotropins should be stopped.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Ovarian neoplasms: Benign and malignant neoplasms have been reported (infrequently) in women receiving multiple-drug therapy for controlled ovarian stimulation; causal effect has not been established.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Ovarian torsion: Has been reported following gonadotropin treatment; may be related to OHSS, prior ovarian torsion, prior or current ovarian cyst, polycystic ovaries, pregnancy, or prior abdominal surgery. Early diagnosis and prompt detorsion may limit the extent of ovarian damage.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pulmonary effects: Serious pulmonary conditions (atelectasis, acute respiratory distress syndrome, and exacerbation of asthma) have been reported.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Thromboembolic events: In association with and separate from ovarian hyperstimulation syndrome (OHSS), thromboembolic events have been reported.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Multiple-dose injection pens: According to the Centers for Disease Control and Prevention (CDC), pen-shaped injection devices should never be used for more than one person (even when the needle is changed) because of the risk of infection. The injection device should be clearly labeled with individual patient information to ensure that the correct pen is used (CDC, 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: To minimize risks, use only at the lowest effective dose. Monitor ovarian response with serum estradiol and vaginal ultrasound on a regular basis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Experienced physician: These medications should only be used by physicians who are thoroughly familiar with infertility problems and their management.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Multiple births: May result from the use of these medications; advise patient of the potential risk of multiple births before starting the treatment.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299360\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6220486\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=8923&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:0em;display:inline\">There are no known significant interactions.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3882606\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">X (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3882607\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Ectopic pregnancy, congenital abnormalities, spontaneous abortion, and multiple births have been reported. The incidence of congenital abnormality may be slightly higher after ART than with spontaneous conception; higher incidence may be related to parenteral characteristics (maternal age, sperm characteristics). Follitropin Alfa is used for the induction of ovulation; use is contraindicated in women who are already pregnant.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16355452\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if follitropin alfa is excreted in breast milk. Due to the potential for serious adverse reactions in the nursing infant, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of treatment to the mother.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3882639\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Monitor sufficient follicular maturation. This may be directly estimated by sonographic visualization of the ovaries and endometrial lining or measuring serum estradiol levels. The combination of both ultrasonography and measurement of estradiol levels is useful for monitoring for the growth and development of follicles and timing hCG administration.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">The clinical evaluation of estrogenic activity (changes in vaginal cytology and changes in appearance and volume of cervical mucus) provides an indirect estimate of the estrogenic effect upon the target organs and, therefore, it should only be used adjunctively with more direct estimates of follicular development (ultrasonography and serum estradiol determinations).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">The clinical confirmation of ovulation is obtained by direct and indirect indices of progesterone production or by sonographic evidence. The indices of progesterone production most generally used are: urinary or serum luteinizing hormone (LH) rise, rise in basal body temperature, increase in serum progesterone, and menstruation following the shift in basal body temperature. The indices of sonographic evidence of ovulation include: Collapsed follicle, fluid in the cul-de-sac, features consistent with corpus luteum formation, or secretory endometrium.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Monitor for signs and symptoms of OHSS for at least 2 weeks following hCG administration.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">OHSS: Monitoring of hospitalized patients should include abdominal circumference, albumin, cardiorespiratory status, electrolytes, fluid balance, hematocrit, hemoglobin, serum creatinine, urine output, urine specific gravity, vital signs, weight (all daily or as necessary), and liver enzymes (weekly) (SOGC-CFAS 2011).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Spermatogenesis: Monitor serum testosterone levels, sperm count</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3882624\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Follitropin alfa is a human FSH preparation of recombinant DNA origin. Follitropins stimulate ovarian follicular growth in women who do not have primary ovarian failure, and stimulate spermatogenesis in men with hypogonadotrophic hypogonadism. FSH is required for normal follicular growth, maturation, gonadal steroid production, and spermatogenesis. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3882626\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset of action: Peak effect:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Spermatogenesis, median: 6.8-12.4 months (range 2.7-18.1 months) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Follicle development: Within cycle</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: SubQ: Absorption rate is slower than the elimination rate</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: Mean V<sub>d</sub>: 0.7 L with <i>in vitro</i> fertilization/embryo transfer patients</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bioavailability: ~66% to 76% in healthy female volunteers; 10% in <i>in vitro</i> fertilization/embryo transfer patients</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">SubQ: 24-53 hours in healthy female volunteers; 32-41 hours in healthy male volunteers</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak: In healthy volunteers: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Females: SubQ: 8-16 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Males: SubQ: 11-20 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Clearance: IV: 0.6 L/hour in healthy female volunteers</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4370386\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Gonal-f RFF Rediject Subcutaneous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">300 units/0.5 mL (0.5 mL): $829.34</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">450 unit/0.75 mL (0.75 mL): $1,244.02</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">900 unit/1.5 mL (1.5 mL): $2,488.03</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Gonal-f Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">450 unit (1): $1,244.02</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1050 unit (1): $2,902.70</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Gonal-f RFF Subcutaneous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">75 unit (1): $207.34</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4301369\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Bemfola (BE, CZ, DE, DK, EE, ES, FI, FR, GB, HR, HU, IE, IL, IS, LT, LU, LV, MT, NO, PL, PT, RO, SE, SI, SK);</li>\n      <li>Forielle (CH);</li>\n      <li>Gonal-F (AE, AR, AT, AU, BE, BG, BH, BR, CH, CL, CN, CO, CR, CU, CY, CZ, DE, DK, DO, EC, EE, EG, ES, FI, FR, GB, GR, GT, HK, HN, HR, HU, ID, IE, IL, IN, IS, IT, JO, KR, KW, LB, LK, LT, LU, LV, MT, MX, MY, NI, NL, NO, NZ, PA, PH, PK, PL, PT, QA, RO, RU, SA, SE, SG, SI, SK, SV, TH, TR, TW, VN, ZA);</li>\n      <li>Gonalef (JP, VE);</li>\n      <li>Honal-F (UA);</li>\n      <li>Ovaleap (CZ, DE, DK, ES, FR, GB, HR, HU, IE, LT, LU, LV, MT, PL, PT, RO, SK)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    American Association of Clinical Endocrinologists, &ldquo;American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the Evaluation and Treatment of Hypogonadism in Adult Male Patients &minus; 2002 Update,&rdquo; <i>Endocr Pract</i>, 2002, 8(6):440-56.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/follitropin-alfa-recombinant-human-follicle-stimulating-hormone-drug-information/abstract-text/15260010/pubmed\" target=\"_blank\" id=\"15260010\">15260010</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC). CDC clinical reminder: insulin pens must never be used for more than one person. Centers for Disease Control and Prevention Web site. <a href=\"http://www.cdc.gov/injectionsafety/clinical-reminders/insulin-pens.html\" target=\"_blank\">http://www.cdc.gov/injectionsafety/clinical-reminders/insulin-pens.html</a>. Updated January 5, 2012. Accessed January 9, 2012.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Corbett S, Shmorgun D, Claman P, et al; Reproductive Endocrinology Infertility Committee. The prevention of ovarian hyperstimulation syndrome. <i>J Obstet Gynaecol Can</i>. 2014;36(11):1024-1033. doi: 10.1016/S1701-2163(15)30417-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/follitropin-alfa-recombinant-human-follicle-stimulating-hormone-drug-information/abstract-text/25574681/pubmed\" target=\"_blank\" id=\"25574681\">25574681</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fiedler K, Ezcurra D. Predicting and preventing ovarian hyperstimulation syndrome (OHSS): the need for individualized not standardized treatment. <i>Reprod Biol Endocrinol</i>. 2012;10:32. doi: 10.1186/1477-7827-10-32.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/follitropin-alfa-recombinant-human-follicle-stimulating-hormone-drug-information/abstract-text/22531097/pubmed\" target=\"_blank\" id=\"22531097\">22531097</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Goa KL and Wagstaff AJ, &ldquo;Follitropin Alpha in Infertility,&rdquo; <i>BioDrugs</i>, 1998, 9(3):235-60.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/follitropin-alfa-recombinant-human-follicle-stimulating-hormone-drug-information/abstract-text/18020563/pubmed\" target=\"_blank\" id=\"18020563\">18020563</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gonal-f for injection (follitropin alfa) [prescribing information]. Rockland, MA: EMD Serono, Inc; January 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gonal-f for subcuteneous injection (follitropin alfa) [prescribing information]. Rockland, MA: EMD Serono, Inc; December 2012.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gonal-f RFF Redi-ject for subcuteneous injection (follitropin alfa) [prescribing information]. Rockland, MA: EMD Serono, Inc; January 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Petak SM, Nankin HR, Spark RF, et al, &ldquo;American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the Evaluation and Treatment of Hypogonadism in Adult Male Patients -- 2002 Update,&rdquo; <i>Endocr Pract</i>, 2002, 8(6):440-56.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/follitropin-alfa-recombinant-human-follicle-stimulating-hormone-drug-information/abstract-text/15260010/pubmed\" target=\"_blank\" id=\"15260010\">15260010</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Practice Committee of the American Society for Reproductive Medicine. Prevention and treatment of moderate and severe ovarian hyperstimulation syndrome: a guideline. <i>Fertil Steril</i>. 2016;106(7):1634-1647. doi: 10.1016/j.fertnstert.2016.08.048.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/follitropin-alfa-recombinant-human-follicle-stimulating-hormone-drug-information/abstract-text/27678032/pubmed\" target=\"_blank\" id=\"27678032\">27678032</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shmorgun D, Claman P, Gysler M, Hemmings R; Joint Society of Obstetricians and Gynaecologists of Canada-Canadian Fertility and Andrology Society (SOGC-CFAS) Clinical Practice Guidelines Committee. The diagnosis and management of ovarian hyperstimulation syndrome: No. 268, November 2011. <i>Int J Gynaecol Obstet</i>. 2012;116(3):268-273.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/follitropin-alfa-recombinant-human-follicle-stimulating-hormone-drug-information/abstract-text/22416285/pubmed\" target=\"_blank\" id=\"22416285\">22416285</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Williams RS, Vensel T, Sistrom CL, et al, &ldquo;Pregnancy Rates in Varying Age Groups After <i>in vitro</i> Fertilization: A Comparison of Follitropin Alfa (Gonal F) and Follitropin Beta (Follistim),&rdquo; <i>Am J Obstet Gynecol</i>, 2003, 189(2):342-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/follitropin-alfa-recombinant-human-follicle-stimulating-hormone-drug-information/abstract-text/14520188/pubmed\" target=\"_blank\" id=\"14520188\">14520188</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 8923 Version 107.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F3882602\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F3888769\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F3882605\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F3882635\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F3882636\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F13812856\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F13812857\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F242582\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F3882604\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F3882637\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F242583\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F3882614\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F3882610\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F3882611\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299360\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F6220486\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F3882606\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F3882607\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F16355452\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F3882639\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F3882624\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F3882626\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F4370386\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F4301369\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/8923|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=follitropin-alfa-recombinant-human-follicle-stimulating-hormone-patient-drug-information\" class=\"drug drug_patient\">Follitropin alfa (recombinant human follicle stimulating hormone): Patient drug information</a></li></ul></div></div>","javascript":null}